214 reports of this reaction
1.6% of all GLUCAGON reports
#8 most reported adverse reaction
HAEMOPTYSIS is the #8 most commonly reported adverse reaction for GLUCAGON, manufactured by Amphastar Pharmaceuticals, Inc.. There are 214 FDA adverse event reports linking GLUCAGON to HAEMOPTYSIS. This represents approximately 1.6% of all 13,146 adverse event reports for this drug.
Patients taking GLUCAGON who experience haemoptysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOPTYSIS is a less commonly reported adverse event for GLUCAGON, but still significant enough to appear in the safety profile.
In addition to haemoptysis, the following adverse reactions have been reported for GLUCAGON:
The following drugs have also been linked to haemoptysis in FDA adverse event reports:
HAEMOPTYSIS has been reported as an adverse event in 214 FDA reports for GLUCAGON. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOPTYSIS accounts for approximately 1.6% of all adverse event reports for GLUCAGON, making it a notable side effect.
If you experience haemoptysis while taking GLUCAGON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.